Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma 18 lat lub więcej.
- •Ogólny stan zdrowia pacjenta jest dobry (skala ECOG 0-1).
- •Narządy pacjenta działają prawidłowo.
- •Rak trzustki lub rak jelita grubego potwierdzony badaniami.
- •Choroba jest w stadium zaawansowanym (przerzuty lub nieoperacyjna).
✗ Disqualifies
- •Choroba nowotworowa obejmująca mózg.
- •Problemy z wchłanianiem leków w przewodzie pokarmowym.
- •Duża operacja w ciągu ostatnich 28 dni przed pierwszym podaniem leku.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (32)
Ironwood Cancer and Research Centers
Chandler, United States
Mayo Clinic Hospital
Phoenix, United States
HonorHealth Research Institute
Scottsdale, United States
UC San Diego Moores Cancer Center
La Jolla, United States
Cedars-Sinai Cancer at Cedars-Sinai Medical Center
Los Angeles, United States
UCLA Hematology/Oncology- Santa Monica
Los Angeles, United States
University of Colorado Hospital-Anschutz Cancer Pavilion
Aurora, United States
Yale-New Haven Hospital-Yale Cancer Center
New Haven, United States
Mayo Clinic Cancer Center
Jacksonville, United States
Moffitt Cancer Center
Tampa, United States
The University of Kansas Clinical Research Center
Westwood, United States
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Baltimore, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Mayo Clinic
Rochester, United States
Nebraska Cancer Specialists
Omaha, United States
University of Nebraska Medical Center
Omaha, United States
Atlantic Health System
Morristown, United States
Northwell Health / RJ Zuckerberg Cancer Center
Lake Success, United States
Columbia University Medical Center
New York, United States
Memorial Sloan Kettering Cancer Center Main Campus
New York, United States
Duke University Medical Center
Durham, United States
University of Cincinnati Medical Center
Cincinnati, United States
Stephenson Cancer Center
Oklahoma City, United States
Hospital of the University of Pennsylvania
Philadelphia, United States
SCRI Oncology Partners
Nashville, United States
Baylor College of Medicine
Houston, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
NEXT Oncology Dallas
Irving, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, United States
Virginia Cancer Specialists
Fairfax, United States
Fred Hutchinson Cancer Center
Seattle, United States
Trial contact
Revolution Medicines
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.